Hypoloc

Nebivolol, the active ingredient in Hypoloc, is a beta blocker (selective β1‑adrenergic antagonist) presented as an oral tablet for oral use. It treats hypertension and heart failure in adult patients.

GNH USA supplies Hypoloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular disease management. - Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Heart failure: improves left‑ventricular function and decreases hospitalization rates. - Left ventricular dysfunction: supports cardiac output in patients with reduced ejection fraction.

Nebivolol may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: often related to blood‑pressure lowering. - Fatigue: general tiredness or lack of energy. - Nasal congestion: mild blockage of nasal passages. - Diarrhea: loose stools, usually transient. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Acute heart failure decompensation: worsening of heart failure symptoms. - Bronchospasm: constriction of airways, especially in patients with asthma. - Liver enzyme elevation: abnormal hepatic function tests.

Nebivolol requires careful assessment before and during therapy. - Cardiovascular assessment: evaluate heart rate, blood pressure, and cardiac function. - Concomitant β‑blockers: avoid additive effects that may cause excessive bradycardia. - Renal impairment: adjust monitoring as clearance may be reduced. - Hepatic disease: use with caution in patients with liver dysfunction. - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: may cause profound bradycardia and hypotension. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma levels. - Calcium channel blockers (verapamil, diltiazem): additive negative‑inotropic and AV‑node effects.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate orthostatic hypotension. - Antihypertensive agents (ACE inhibitors, ARBs): monitor for excessive blood‑pressure reduction. - Antidiabetic drugs: beta‑blockade can mask hypoglycaemia symptoms; adjust glucose monitoring.